Schroder Investment Management Group’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-538,036
| Closed | -$25.9M | – | 1172 |
|
|
2025
Q3 | $25.9M | Sell |
538,036
-354,318
| -40% | -$21.9M | 0.02% | 466 |
|
|
2025
Q2 | $66.6M | Sell |
892,354
-72,830
| -8% | -$4.82M | 0.06% | 235 |
|
|
2025
Q1 | $61.3M | Buy |
965,184
+70,645
| +8% | +$4.8M | 0.06% | 244 |
|
|
2024
Q4 | $69.8M | Sell |
894,539
-42,750
| -5% | -$3.43M | 0.07% | 233 |
|
|
2024
Q3 | $75.3M | Buy |
937,289
+11,719
| +1% | +$947K | 0.08% | 215 |
|
|
2024
Q2 | $76.6M | Buy |
925,570
+297,551
| +47% | +$26.2M | 0.08% | 200 |
|
|
2024
Q1 | $53.6M | Sell |
628,019
-28,791
| -4% | -$2.26M | 0.06% | 274 |
|
|
2023
Q4 | $56.2M | Sell |
656,810
-115,131
| -15% | -$9.95M | 0.07% | 250 |
|
|
2023
Q3 | $69.2M | Sell |
771,941
-224,267
| -23% | -$20M | 0.1% | 193 |
|
|
2023
Q2 | $84.8M | Buy |
996,208
+50,584
| +5% | +$4.28M | 0.12% | 167 |
|
|
2023
Q1 | $78.3M | Sell |
945,624
-7,359
| -0.8% | -$596K | 0.12% | 178 |
|
|
2022
Q4 | $75M | Sell |
952,983
-30,014
| -3% | -$2.41M | 0.12% | 178 |
|
|
2022
Q3 | $72.8M | Buy |
982,997
+218,886
| +29% | +$15.7M | 0.12% | 169 |
|
|
2022
Q2 | $49.8M | Buy |
764,111
+274,774
| +56% | +$16.3M | 0.08% | 257 |
|
|
2022
Q1 | $30.9M | Sell |
489,337
-56,484
| -10% | -$3.07M | 0.04% | 390 |
|
|
2021
Q4 | $28.9M | Buy |
545,821
+117,789
| +28% | +$7.18M | 0.04% | 394 |
|
|
2021
Q3 | $30.2M | Sell |
428,032
-107,902
| -20% | -$6.81M | 0.05% | 388 |
|
|
2021
Q2 | $35.7M | Buy |
535,934
+237,574
| +80% | +$16.8M | 0.04% | 378 |
|
|
2021
Q1 | $33.1M | Buy |
298,360
+92,266
| +45% | +$11.4M | 0.04% | 394 |
|
|
2020
Q4 | $24.5M | Buy |
+206,094
| New | +$22.2M | 0.03% | 432 |
|
|
2019
Q2 | – | Sell |
-9,465
| Closed | -$828K | – | 1228 |
|
|
2019
Q1 | $828K | Sell |
9,465
-170,690
| -95% | -$15.5M | ﹤0.01% | 940 |
|
|
2018
Q4 | $18M | Buy |
180,155
+168,048
| +1,388% | +$17.7M | 0.03% | 459 |
|
|
2018
Q3 | $1.39M | Hold |
12,107
| – | – | ﹤0.01% | 862 |
|
|
2018
Q2 | $1.08M | Sell |
12,107
-8,762
| -42% | -$740K | ﹤0.01% | 917 |
|
|
2018
Q1 | $1.53M | Hold |
20,869
| – | – | ﹤0.01% | 889 |
|
|
2017
Q4 | $1.21M | Sell |
20,869
-15,325
| -42% | -$807K | ﹤0.01% | 953 |
|
|
2017
Q3 | $1.56M | Buy |
+36,194
| New | +$1.5M | ﹤0.01% | 913 |
|
|
2014
Q2 | – | Sell |
-257,300
| Closed | -$8.39M | – | 1407 |
|
|
2014
Q1 | $8.39M | Buy |
257,300
+3,300
| +1% | +$126K | 0.01% | 670 |
|
|
2013
Q4 | $10.7M | Sell |
254,000
-198,700
| -44% | -$8.18M | 0.01% | 629 |
|
|
2013
Q3 | $18.1M | Sell |
452,700
-114,100
| -20% | -$4.79M | 0.04% | 469 |
|
|
2013
Q2 | $23.4M | Buy |
+566,800
| New | +$22.9M | 0.06% | 375 |
|
Other funds holding HAE
Schroder Investment Management Group's HAE Position: Q4 2025 in Review
Schroder Investment Management Group sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 538,036 shares — an estimated $25.9M sold.
Schroder Investment Management Group first reported a position in HAE in Q2 2013 and held it in 31 quarters. The position peaked at $84.8M in Q2 2023. 329 funds tracked by Wall St. Rank hold HAE as of Q4 2025.
- Schroder Investment Management Group reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
- Schroder Investment Management Group sold 538,036 Haemonetics shares in Q4 2025, an estimated $25.9M.
- Schroder Investment Management Group first reported a position in Haemonetics in Q2 2013 and held it in 31 quarters.
- Schroder Investment Management Group's Haemonetics position peaked at $84.8M in Q2 2023.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.
Based on Schroder Investment Management Group's 13F filing for Q4 2025, filed 13 Feb 2026.